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Background: Gadd45a is a member of the Gadd45 family of genes that are known stress sensors. Gadd45a has
been shown to serve as an effector in oncogenic stress in breast carcinogenesis in murine models. The present
study was aimed at clarifying the expression of Gadd45a in human breast cancer and its correlation with
clinicopathologic features.
Methods: The expression levels of Gadd45a in breast tissue samples of female breast surgery cases were examined
by immunohistochemistry (IHC) using a Gadd45a antibody. Percent staining was determined and statistical analyses
were applied to determine prognostic correlations.
Results: 56 female breast surgery cases were studied: Normal (11), Luminal A (9), Luminal B (11), HER2+ (10), Triple
Negative (15). There was a highly significant difference in percent Gadd45a staining between groups [Mean]:
Normal 16.3%; Luminal A 65.3%; Luminal B 80.7%; HER2+ 40.5%; TN 32%, P < 0.001, ANOVA. Gadd45a IHC levels for
Normal cases found 82% negative/low. Luminal A breast cancer cases were found to be 67% high. Luminal B breast
cancers were 100% high. Her2+ cases were 50% negative/low. Triple Negative cases were 67% negative/low. This
difference in distribution of Gadd45a levels across breast cancer receptor subtypes was significant, P = 0.0009.
Conclusions: Gadd45a levels are significantly associated with hormone receptor status in human breast cancer.
Normal breast tissue displays low Gadd45a levels. High Gadd45a levels are associated with Luminal A and Luminal
B subtypes. Absence of hormone receptors in Triple Negative subtype is associated with Negative/Low levels of
Gadd45a. Further studies are indicated to elucidate the role of Gadd45a in breast cancer as a potential
prognosticator or target for treatment.
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In the United States, breast cancer is the most common
non-skin cancer among women, with an estimated
230,000 cases diagnosed in 2012 [1,2]. It is also one of
the leading causes of cancer death among women of all
races and Hispanic origin populations. However, a full
understanding of the molecular mechanisms that con-
tribute to the malignant growth of breast cancer cells re-
mains unclear. Therefore, understanding the complete
biology of breast cancer is an important aspect for iden-
tifying therapeutic targets.* Correspondence: lieberma@temple.edu
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reproduction in any medium, provided the orGadd45a is a member of the Gadd45 family of genes
that are known stress sensors, which modulates the cel-
lular response to a variety of stress conditions, including
genotoxic and oncogenic stress [3-6]. The complex role
of stress sensors in monitoring tumor development is
not fully understood, the best example being the mul-
tiple functions attributed to p53 in tumor development
and suppression [7,8]. Gadd45a is a transcriptional target
for tumor suppressors p53 and BRCA1, whose loss of
function play key roles in cancer development, including
breast tumorigenesis [7,8].
In murine models, Gadd45a functions to either pro-
mote or suppress breast tumor development via engage-
ment of different signaling pathways depending on the
molecular nature of the activated oncogene [9,10]. Al-
though data suggests that Gadd45a may have a functiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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been no reports on whether the expression of Gadd45a
is correlated with any clinicopathological characteristics.
The present study was aimed at clarifying the expres-
sion of Gadd45a in human breast cancer and correlation
of its expression with clinicopathologic features, such as
hormone receptor status. In this study, we report for the
first time the expression pattern of Gadd45a in breast
cancer. We found that the expression levels of Gadd45a
are hormone receptor dependent. Our results suggest
that Gadd45a may play a role in breast cancer pathogen-
esis and could be used as a biomarker for breast cancer
prognosis.
Methods
Tissue samples and patient clinical information
A total of 56 formalin-fixed paraffin embedded tissue
samples were analyzed in this study, 45 primary breast
carcinomas and 11 normal breast tissue. Normal sam-
ples were obtained from patients who had undergone re-
duction mammaplasty surgery at Temple University
Hospital. Breast carcinoma samples were obtained from
patients who had undergone surgery and were histo-
pathologically and clinically diagnosed from 2005 to
2011. Clinical diagnosis and staging were determined
according to the WHO tumor classification (Inter-
national Classification of Diseases in Oncology) [11] and
the AJCC Cancer Staging Manual (7th Edition) [12]. The
histopatholgical grading was done according to the
modified Bloom and Richardson system [11]. All work
was performed under a Temple University Institutional
Review Board approved protocol (Protocol Number
12485). Patient consent was obtain according to guide-
lines. Table 1 summarizes clinical and pathological infor-
mation for all patients.
Immunohistochemistry
Immunohistochemical analysis was performed on 56 hu-
man breast tissues. To summarize, paraffin-embedded
tissue slides were deparaffinized, rehydrated and subjec-
ted to antigen unmasking by sodium citrate (pH 6.0) for
30 minutes at a sub-boiling temperature. Endogenous
peroxidase activity was blocked by incubation in 3%
hydrogen peroxide for 10 minutes. Sections were
blocked with 5% serum for one hour at room tempera-
ture, followed by incubation with primary antibody
overnight at 4°C. (Gadd45A - Abcam (ab7664)). For a
negative control, the anti–Gadd45a antibody was re-
placed with normal goat serum. Sections were incubated
with a peroxidase-conjugated secondary antibody for
30 min at room temperature, followed by treatment with
ABC reagent (Vector Laboratories) for 30 min. Sections
were stained with 3,3′-diaminobenzidine substrate
and counterstained with hematoxylin, dehydrated andmounted in Permount (Fisher Scientific). Slides were
prepared in triplicate. The degree of immunostaining
was reviewed independently by three observers, includ-
ing an attending pathologist. Percent positive stainings
for each specimen were averaged and categorized as:
Negative/Low (0- < 30%, Neg), Medium (30–60%, Med),
or High (>60%).
Statistical analysis
All statistical analyses were carried out using GraphPad
Prism Statistical Software. ANOVA was used to analyze
the correlation between the mean percent Gadd45a
staining and the clinicopathological characteristics. Chi
Square Analysis was performed on percent staining cat-
egories. P < 0.05 in all cases was considered statistically
significant.
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Elevated expression of Gadd45a in primary breast tumors
To investigate Gadd45a expression in human breast can-
cer, 45 previously characterized human female mammary
carcinoma samples and 11 normal mammary samples
were evaluated for Gadd45a expression by immunohisto-
chemistry analysis with an antibody against Gadd45a. We
found that Gadd45a was significantly overexpressed in
breast cancer tissues compared to normal tissues obtained
from patients who underwent reduction mammaplasty.
(P < 0.001, Figure 1A). High levels of strong cytoplasmic
staining of Gadd45a were present in areas containing can-
cer cells of the primary breast tumors. In addition, strong
cytoplasmic staining of Gadd45a was also detected in adja-
cent noncancerous epithelial cells (Figure 1B). Taken to-
gether, these observations demonstrate that high levels of
Gadd45a expression are correlated with the development
of primary breast carcinoma.Figure 1 Gadd45a expression levels are elevated in human breast can
graphically depicting Gadd45a expression in human breast samples, demo
compared to normal tissue samples. Statistical significance was achieved b
(P < 0.001, t-test). (B) Representative images from immunohistochemical an
and (c) normal epithelial cells adjacent to cancer cells.Gadd45a Expression is elevated in luminal A and luminal B
breast cancers
In order to assess if Gadd45a expression levels corre-
lated with any of breast cancer subtypes, the 56
breast surgery cases were grouped as follows: Normal
(11, benign mammoplasty), Luminal A (9, ER+, PR+,
HER2-; LumA), Luminal B (11, ER+, PR+, HER2+),
HER2+ (10, ER-, PR-, HER2+), and Triple Negative
(15, ER-, PR-, HER2-; TN ). There was a highly sig-
nificant difference in percent Gadd45a staining be-
tween groups as measured by mean percent staining:
Normal 16.3%; LumA 65.3%; LumB 80.7%; HER2+
40.5%; TN 32% (Figure 2A). Figure 2B illustrates high
levels of Gadd45a in Luminal A and Luminal B breast
cancers. However, in Her2+/Neu and Triple Negative
breast cancers, the levels of Gadd45a were low, simi-
lar to the levels observed in normal breast tissue. The
observed differences in Gadd45a expression withincer samples compared to normal tissue. (A) Box and Whisker Plots,
nstrate elevated levels of Gadd45a expression in carcinoma samples
etween differences in mean percent staining between the two groups
alysis of Gadd45a on (a) normal breast tissue, (b) breast cancer tissue
Figure 2 Gadd45A expression levels in human breast cancer samples are dependent on the hormone receptor subtype. (A) Box and
Whisker Plots graphically depict the expression pattern of Gadd45a in the subtypes of human breast cancer. There was a highly significant
difference in percent Gadd45a staining between groups: Normal 16.3%; Luminal A 65.3%; Luminal B 85.7%; HER2+ 40.5%; TN 31.2%, P < 0.001,
ANOVA. (B) Representative images from immunohistochemical analysis of Gadd45a of Normal (a), Luminal A (b), Luminal B (c), Her2+ (d) and
Triple Negative (e) breast tissue. Immunostaining was reviewed and scored by three independent observes. Percent positive stainings for each
specimen were averaged and categorized as: Negative (0- < 10%, Neg), Low (10–<40%), Medium (40–<70%, Med), or High (≥70%).
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significant (P < 0.001, ANOVA).
The levels of Gadd45a expression, as calculated by
percent staining for each specimen, were averaged and
categorized as: Negative Low (<30%), Medium (31–60%,
Med), or High (>60%). As seen in Table 2, Gadd45a
expression levels for Normal cases found 81% low.
Luminal A breast cancer cases were found to be 67%
high. Luminal B breast cancers were 100% high. Her2+/
Neu cases were 50% low, 20% med, 30% high. Triple
Negative cases were 67% low. The difference in distribu-
tion of Gadd45a levels across breast cancer receptorTable 2 Chi square analysis of gadd45a expression levels bet
Normal Luminal A
Neg/Low <30 9 2
Medium 31–60 1 1
High >60 1 6
Chi Square P = 0.0009.subtypes was significant (P = 0.0009, Chi Squared test).
Taken together, these data provide evidence that Gadd
45a expression in breast cancer is elevated in Luminal A
and Luminal B human breast cancer.
Gadd45a Expression correlates with hormone receptor
status
Statistical analyses were performed to examine the
correlation between Gadd45a expression levels and vari-
ous clinicopatholgical characteristics of breast cancer.
No correlation was found between Gadd45a expression
levels and cancer grade, patient age, Her2/Neu receptorween breast cancer subtypes
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seen in Table 3, the expression of Gadd45a strongly
correlated with ER/PR receptor status (P <0.001, Chi
Squared test). Together, these data provide evidence that
Gadd45a expression is Estrogen and/or Progesterone
hormone receptor dependent.
Discussion
We demonstrate for the first time that the expression
levels of Gadd45a are hormone receptor status depen-
dent, where high levels of Gadd45a correlate with ER+/
PR + breast cancers. Gadd45a protein levels are elevated
in human breast carcinoma, demonstrated by immuno-
histochemical staining. Our data presented here provides
evidence that elevated expression of Gadd45a correlates
with ER+/PR+, Luminal A and Luminal B breast cancers,
whereas low expression of Gadd45a correlates with ER-/
PR-, Her2+ and Triple Negative breast cancers. Taken to-
gether, our work provides evidence that Gadd45a may play
a role in breast cancer pathogenesis and may represent a
novel prognostic factor for breast cancer.
In the sample population from this study, the estrogen
receptor and progesterone receptor status were concord-
ant in all but one case, where the patient was ER+/PR-.
Therefore, we were unable to discern whether Gadd45a
expression correlates with estrogen receptor alone, pro-
gesterone receptor alone or in unison with both estrogen
and progesterone receptor. Experiments are underway to
address this question.
In addition to strong cytoplasmic staining of tumor
cells, we find strong cytoplasmic staining in adjacent
noncancerous epithelial cells. Knowing that Gadd45a is
a stress sensor, playing a role in the cellular response to
oncogenic stress, this finding supports the notion that
Gadd45a may modulate the cellular response to onco-
genic stress in surrounding noncancerous cells in human
breast tissue thus playing a role in breast cancer patho-
genesis. Future experiments are planned to further in-
vestigate the role Gadd45a plays in modulating the
response of normal breast epithelial cells to adjacent
cancerous cells.
Previously published studies have shown that Gadd45a
plays a role in murine breast carcinoma [9,10]. Gadd45a






Her2/Neu- 44.5 36.32343tumorigenesis by increasing JNK-mediated apoptosis and
p38-mediated senescence. In contrast, Gadd45a functions
to promote Myc-driven breast cancer by negatively regu-
lating MMP10 via GSK3B/B-catenin signaling, resulting in
increased tumor vascularization and growth. Therefore,
we choose to examine the expression patterns of these
known Gadd45a effector proteins to provide insight into
the functional role of Gadd45a in human breast cancer.
Correlations between expression levels of Gadd45a and
expression levels of activated JNK, p38, MMP10, GSK3B
and B-catenin were examined. However, no correlations
were found. Thus, additional experiments must be carried
out to elucidate the molecular mechanism of Gadd45a
modulation of human breast cancer.
A search for Gadd45a on public cancer microarray da-
tabases fails to provide statistically significant data to
support our findings in this report that Gadd45a expres-
sion is elevated based on hormone receptor status.
However, many microarray datasets do not allow for
grouping based on clinicopatholgical characteristic pa-
rameters while analyzing the data. For those datasets
that do allow for segregation based on those features, we
believe that the discrepancy may be due to the fact that
Gadd45a may not be regulated solely at the transcription
level, but rather regulated at various levels.
In conclusion, Gadd45a levels in human breast cancer
are significantly associated with hormone receptor sta-
tus. Normal breast tissue has low levels of Gadd45a.
Gadd45a levels are elevated in Luminal A subtypes,
highest in Luminal B subtypes, lower in HER + subtypes
and lowest in Triple Negative subtypes. In combination
with other biomarkers of breast cancer, Gadd45a expres-
sion status may be useful for determining which thera-
peutic strategies against breast cancer are employed.
Moreover, investigation of mechanisms that regulate
Gadd45a expression during breast carcinogenesis and a
more complete understanding of the role Gadd45a ex-
pression and signaling play in breast cancer pathogenesis
may provide novel therapeutic targets.
Conclusions
Gadd45a levels are significantly associated with hormone
receptor status in human breast cancer. Normal breast
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Moderate levels of Gadd45a are associated with Her2
subtype samples. Absence of hormone receptors in
Triple Negative subtype is associated with Negative/Low
levels of Gadd45a. Our results suggest that Gadd45a
may play a role in breast cancer pathogenesis and could
be used as a biomarker for breast cancer prognosis.
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